Shanu Modi

19.5k total citations · 6 hit papers
233 papers, 8.6k citations indexed

About

Shanu Modi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Shanu Modi has authored 233 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Oncology, 101 papers in Pulmonary and Respiratory Medicine and 79 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Shanu Modi's work include HER2/EGFR in Cancer Research (137 papers), Cancer Treatment and Pharmacology (78 papers) and Advanced Breast Cancer Therapies (63 papers). Shanu Modi is often cited by papers focused on HER2/EGFR in Cancer Research (137 papers), Cancer Treatment and Pharmacology (78 papers) and Advanced Breast Cancer Therapies (63 papers). Shanu Modi collaborates with scholars based in United States, Japan and Spain. Shanu Modi's co-authors include Sarat Chandarlapaty, Joshua Z. Drago, Ian E. Krop, Clifford A. Hudis, Komal Jhaveri, Larry Norton, Gabriela Chiosis, Tony Taldone, Hiroji Iwata and Shunji Takahashi and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Shanu Modi

221 papers receiving 8.5k citations

Hit Papers

Unlocking the potential of antibody–drug conjugates for c... 2019 2026 2021 2023 2021 2020 2021 2019 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Unlocking the potential of antibody–drug conjugates for cancer therapy
    2021 751 citations Joshua Z. Drago, Shanu Modi et al. profile →
  2. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
    2020 551 citations Shanu Modi, Haeseong Park et al. Journal of Clinical Oncology profile →
  3. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
    2021 275 citations Paolo Tarantino, Shanu Modi et al. profile →
  4. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
    2019 258 citations Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology profile →
  5. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
    2022 121 citations Shanu Modi, Hiroji Iwata et al. ESMO Open profile →
  6. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
    2024 45 citations Sarat Chandarlapaty, Shanu Modi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shanu Modi United States 46 5.8k 2.9k 2.7k 2.0k 1.1k 233 8.6k
David Miles United Kingdom 37 6.0k 1.0× 2.7k 0.9× 2.2k 0.8× 2.2k 1.1× 1.3k 1.3× 94 8.4k
Mark S. Berger United States 25 4.6k 0.8× 2.1k 0.7× 2.3k 0.8× 1.2k 0.6× 743 0.7× 68 6.9k
Luka Milas United States 53 4.5k 0.8× 1.6k 0.6× 3.6k 1.3× 2.8k 1.4× 1.8k 1.7× 201 9.9k
Neil L. Spector United States 36 3.5k 0.6× 1.5k 0.5× 2.1k 0.8× 1.1k 0.5× 609 0.6× 83 5.2k
Suzanne F. Jones United States 42 4.1k 0.7× 827 0.3× 3.6k 1.4× 1.8k 0.9× 1.1k 1.1× 231 7.8k
Joan Albanell Spain 56 7.9k 1.4× 2.4k 0.8× 4.8k 1.8× 2.9k 1.4× 3.0k 2.8× 251 12.6k
Jeffrey A. Drebin United States 47 6.6k 1.1× 1.7k 0.6× 3.2k 1.2× 2.3k 1.1× 1.6k 1.5× 211 11.1k
Donald J. Buchsbaum United States 51 3.4k 0.6× 1.9k 0.7× 4.8k 1.8× 1.1k 0.5× 1.2k 1.1× 281 9.2k
Maurizio Scaltriti United States 53 6.3k 1.1× 2.1k 0.7× 6.0k 2.2× 3.0k 1.5× 2.1k 2.0× 145 12.0k
X. Cynthia United States 46 5.0k 0.9× 689 0.2× 3.1k 1.1× 2.8k 1.4× 2.3k 2.2× 251 8.8k

Countries citing papers authored by Shanu Modi

Since Specialization
Citations

This map shows the geographic impact of Shanu Modi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanu Modi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanu Modi more than expected).

Fields of papers citing papers by Shanu Modi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shanu Modi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanu Modi. The network helps show where Shanu Modi may publish in the future.

Co-authorship network of co-authors of Shanu Modi

This figure shows the co-authorship network connecting the top 25 collaborators of Shanu Modi. A scholar is included among the top collaborators of Shanu Modi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shanu Modi. Shanu Modi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferraro, Emanuela, Pedram Razavi, Shanu Modi, et al.. (2025). Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan. JCO Precision Oncology. 9(9). e2400898–e2400898. 1 indexed citations
2.
Singh, Sukrit, John D. Chodera, Bo Liu, et al.. (2025). Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding. Cancer Discovery. 16(2). 235–249. 3 indexed citations
3.
Ferraro, Emanuela, Andrea V. Barrio, Daniel J. Kelly, et al.. (2024). Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab. npj Breast Cancer. 10(1). 96–96.
4.
5.
Ferraro, Emanuela, Atif J. Khan, George Plitas, et al.. (2024). Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer. Cancer Research. 84(9_Supplement). PO3–4. 1 indexed citations
6.
Moiso, Enrico, Emanuela Ferraro, Luc Cabel, et al.. (2024). Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.. Journal of Clinical Oncology. 42(16_suppl). 1074–1074. 1 indexed citations
7.
Curigliano, Giuseppe, Rebecca Dent, Shanu Modi, et al.. (2024). Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer. ESMO Open. 9(4). 102989–102989. 13 indexed citations
8.
9.
Brezden‐Masley, Christine, Anil A. Joy, Sandeep Sehdev, et al.. (2023). Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Therapeutic Advances in Medical Oncology. 15. 2620176–2620176. 8 indexed citations
10.
Dusza, Stephen W., Elizabeth Quigley, Alina Markova, et al.. (2023). Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients. Breast Cancer Research and Treatment. 203(2). 271–280. 2 indexed citations
11.
Page, David B., Kathryn Beal, Stefanie N. Linch, et al.. (2022). Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases. npj Breast Cancer. 8(1). 50–50. 25 indexed citations
12.
Jhaveri, Komal, Joshua Z. Drago, Payal D. Shah, et al.. (2021). A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research. 27(14). 3867–3875. 26 indexed citations
13.
Tolaney, Sara M., T. Khanh, Joseph P. Eder, et al.. (2020). A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clinical Cancer Research. 26(21). 5588–5597. 15 indexed citations
14.
Tamura, Kenji, Junji Tsurutani, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 816–826. 258 indexed citations breakdown →
15.
Shitara, Kohei, Hiroji Iwata, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 827–836. 162 indexed citations
16.
Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099. 258 indexed citations
17.
18.
Morris, Patrick G., Xi Kathy Zhou, Ginger L. Milne, et al.. (2013). Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. Cancer Prevention Research. 6(5). 428–436. 57 indexed citations
19.
Jhaveri, Komal, Kathy D. Miller, Lee S. Rosen, et al.. (2012). A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clinical Cancer Research. 18(18). 5090–5098. 49 indexed citations
20.
Modi, Shanu, Alison Stopeck, Hannah Linden, et al.. (2011). HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research. 17(15). 5132–5139. 328 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Miles Breakdown of academic impact, for papers by Mark S. Berger Breakdown of academic impact, for papers by Luka Milas Breakdown of academic impact, for papers by Neil L. Spector Breakdown of academic impact, for papers by Suzanne F. Jones Breakdown of academic impact, for papers by Joan Albanell Breakdown of academic impact, for papers by Jeffrey A. Drebin Breakdown of academic impact, for papers by Donald J. Buchsbaum Breakdown of academic impact, for papers by Maurizio Scaltriti Breakdown of academic impact, for papers by X. Cynthia
Rankless by CCL
2026